Baricitinib and tofacitinib off‐target profile, with a focus on Alzheimer's disease

Baricitinib and tofacitinib off‐target profile, with a focus on Alzheimer's disease

Abstract INTRODUCTION Janus kinase (JAK) inhibitors were recently identified as promising drug candidates for repurposing in Alzheimer's disease (AD) due to their capacity to suppress inflammation via modulation of JAK/STAT signaling pathways. Besides interaction with primary therapeutic target...

Full description

Bibliographic Details
Main Authors: Maria L. Faquetti, Laura Slappendel, Hélène Bigonne, Francesca Grisoni, Petra Schneider, Georg Aichinger, Gisbert Schneider, Shana J. Sturla, Andrea M. Burden
Format: Article
Language:English
Published: Wiley 2024-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
Alzheimer's disease
Janus kinase inhibitors
machine learning
off‐target
physiological based pharmacokinetic modeling
target prediction
Online Access:https://doi.org/10.1002/trc2.12445

Internet

https://doi.org/10.1002/trc2.12445

Similar Items